Evidence map›Paper›PMID 36463141›Full record

ArticleBMC health services research2022

Were economic evaluations well reported for the newly listed oncology drugs in China's national reimbursement drug list.

Liu Liu, Zhixin Jiang, Fuming Li, Yan Wei, Jian Ming, Yi Yang, Shimeng Liu, Lizheng Shi, Yingyao Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC health services research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Liu LiuSchool of Public Health, Fudan University, Shanghai, China.
Zhixin JiangSchool of Public Health, Fudan University, Shanghai, China.
Fuming LiSchool of Public Health, Fudan University, Shanghai, China.
Yan WeiSchool of Public Health, Fudan University, Shanghai, China. yanwei@fudan.edu.cn.
Jian MingSchool of Public Health, Fudan University, Shanghai, China.
Yi YangSchool of Public Health, Fudan University, Shanghai, China.
Shimeng LiuSchool of Public Health, Fudan University, Shanghai, China.
Lizheng ShiSchool of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.
Yingyao ChenSchool of Public Health, Fudan University, Shanghai, China. yychen@shmu.edu.cn.

Funding

China Medical Board (CMB) Grant 19-318, A Demonstration Program on Health Technology Assessment in China
6 · The paper itself

Abstract

purposeTo assess the reporting quality of published economic evaluations of the negotiated oncology drugs listed for China's 2020 National Reimbursement Drug List (NRDL).

methodsA comprehensive search was conducted to identify economic evaluation studies of negotiated oncology drugs listed in China's 2020 NRDL using the PubMed/MEDLINE, Embase, Web of Science, CNKI, SinoMed, and WanFang Database up to March 31, 2021. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist scored the reporting quality between 0 and 100. A linear regression analysis was employed to examine the influence of various characteristics on the reporting quality scores.

resultsEighty papers were included in the study, with the majority published during the past decade. Furthermore, more than half of the articles (57.5%, or 46 out of 80) were written in English. The average CHEERS score was 74.63 ± 12.75 and ranged from 43.48 to 93.75. The most inadequately reported items included choice of model, characterization of heterogeneity, and discussion, as well as currency, price date and conversion. Higher scores were associated with articles published from 2019 to 2021 and English publications.

conclusionThe economic evaluation studies of negotiated oncology drugs listed in 2020 NRDL had moderate reporting quality. The Chinese economic evaluation publications could improve the reporting quality if the CHEERS checklist is consistently implemented. Also, the Chinese journals maybe explore introducing a reporting standard for economic evaluations.

Indexed as

Asian PeopleMedical OncologyChecklistChinaCost-Benefit AnalysisHumansChinaEconomic evaluationOncology drugsPrice negotiationReporting quality assessment

Identifiers

PMID36463141
PMCPMC9719239

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.